Amount of potential cash payments that could result from the contingent consideration arrangement.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name:	us-gaap_BusinessAcquisitionContingentConsiderationPotentialCashPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of other deferred costs charged against earnings in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_OtherDeferredCostAmortizationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow associated with other investments held by the entity for investment purposes not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name:	us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Per terms of an exclusive option for the acquisition of a business, the agreed upon purchase price of the outstanding stock if the option to purchase is exercised by the reporting entity.

+ References

No definition available.

+ Details

Name:	vphm_BusinessAcquisitionOptionalPurchaseAgreementOutstandingStockPurchasePrice
Namespace Prefix:	vphm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the option for payment of cash under business development agreement.

+ References

No definition available.

+ Details

Name:	vphm_BusinessDevelopmentAgreementPotentialCashPayment
Namespace Prefix:	vphm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the percentage of subjects planned for the Phase 2 study enrollment.

+ References

No definition available.

+ Details

Name:	vphm_PercentageOfSubjectsPlannedForPhaseTwoStudyEnrollment
Namespace Prefix:	vphm_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Acquisitions, License and Research Agreements (Details 2) (Meritage Pharma, Inc., USD $) In Millions, unless otherwise specified	1 Months Ended		3 Months Ended			6 Months Ended
	Jul. 31, 2013	Dec. 31, 2011	Jun. 30, 2013	Sep. 30, 2012	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
License and research agreements disclosures
Agreed upon purchase price of the outstanding stock per optional purchase agreement		$ 69.9
Maximum
License and research agreements disclosures
Business development agreement, potential cash payment			5.0			5.0
Contingent consideration, potential cash payment		175
Cost-method investment
License and research agreements disclosures
Payment to purchase interest in development company	2.5	7.5		5.0
Percentage of subjects planned for the Phase 2 study enrollment	50.00%
Amortization expense			$ 1.1		$ 0.6	$ 2.2	$ 1.7